Radiation Oncology Clinical Trials

12 trials identified.

NSABP B-51/RTOG 1304 (Breast Cancer)
Principal Investigator: Blitzblau, Rachel
Protocol Number: PRO00054066

Age Group: Adult
Scope: National

Phase: III (Cancer Control)
Disease Site: Breast

Contact: DCI Clinical Research Team, Radiation Oncology
Email:

What is the Condition Being Studied?
Breast cancer with cancer cells in the lymph nodes at the time of diagnosis which clear after chemotherapy and surgery
What is the Purpose of this Study?
We are doing this study to see if participants with cancer cells in the lymph nodes (at the same time that the breast cancer is diagnosed) and have chemotherapy before surgery that clears the cancer cells from the lymph nodes.
Who Can Participate in the Study?
Adult women ages 18 and older who:
- Have completed chemotherapy 
- Have had a mastectomy or lumpectomy with all removed lymph nodes cancer 
- Have no prior history of cancer or chest radiation therapy
- Are not pregnant or nursing
What is Involved?
If you choose to join this study, you will:
- Have a mammogram or MRI of both your breasts
- Have blood tests to check your blood counts
- Have a blood pregnancy test if you are a woman of childbearing potential
-  Be randomized (put into one of two groups by chance like a flip of a coin) after your surgery to one of two groups   
-- Group 1: Patients who have had a lumpectomy will receive radiation therapy to the breast. 
      Patients who have had a mastectomy will not receive radiation therapy
-- Group 2: if you had a lumpectomy, you will receive radiation therapy to your breast and lymph nodes. If you had a mastectomy, you will receive radiation to the area where your breast used to be and to the lymph nodes.
- Continue having mammograms every year until 10 years after you joined the research study

- Be in the study for up to 10 years  
- Have a physical exam every 6 months for the first couple of years
Participating Institutions:
  • Duke University Health System : Radiation Oncology DCI Clinical Research Team
View this trial at ClinicalTrials.gov

SBRT In Early Stage Breast Cancer
Principal Investigator: Blitzblau, Rachel
Protocol Number: PRO00063848

Age Group: Adult
Scope: Local

Phase: II (Cancer Control)
Disease Site: Breast

Contact: DCI Clinical Research Team, Radiation Oncology
Email:

What is the Condition Being Studied?
Early stage breast cancer
What is the Purpose of this Study?
We are doing this study to learn about the cosmetic outcomes in breast cancer patients who are treated with this single dose of radiation. 

This study will also help us learn about how breast cancer responds to radiation so that in the future, radiation can be matched to the patient's particular tumor.
Who Can Participate in the Study?
Adults aged 50 years or older who:
- Are diagnosed with early stage breast cancer 
- Have a tumor that measures less than or equal to 2cm 
- Have a negative pregnancy test
What is Involved?
If you join this study, you will:
- Have a MRI scan and CT scan to find the tumor and create a plan for your radiation treatment
- A single radiation dose of 21 Gy (Gray) will be given to your breast cancer. 
- Surgery will be done to remove your tumor, within 10 days of completing radiation. 
- We will obtain tumor tissue from your surgery to understand how breast cancer responds to radiation. 
- Digital photographs and quality of life questionnaires will be obtained prior to the single radiation dose and at 6 months, 1 year, 2 years and 3 years after treatment. 
-- The photographs will be used to see how your breasts look before and after surgery and radiation treatment. 
Participating Institutions:
  • Duke University Health System : Radiation Oncology DCI Clinical Research Team
View this trial at ClinicalTrials.gov

SIMT Stereotactic Radiosurgery Outcomes Study (Brain Cancers)
Principal Investigator: Kim, Grace
Protocol Number: PRO00075429

Age Group: Adult
Scope: Local

Phase: II (Cancer Control)
Disease Site: Breast; Kidney; Lip, Oral Cavity and Pharynx; Lung; Melanoma, skin

Contact: DCI Clinical Research Team, Radiation Oncology
Email:

What is the Condition Being Studied?
Brain Cancer
What is the Purpose of this Study?
We are doing this study to understand the side effects of treatment and effect on mental functioning in patients that are treated with SRS. 
Who Can Participate in the Study?
Adults who:
- Are diagnosed with 4 -10 brain  tumors, each of which measures less than 4cm.  
- Have had surgery to remove the brain tumors
- Are able to complete MRI imaging
What is Involved?
If you choose to join this study, you will:
- Be asked to complete mental function assessments and quality of life questionnaires before radiation treatment and at all follow up visits. 
- Have a Magnetic resonance imaging (MRI) and Computed Tomography (CT) scans to plan for your radiation dose and delivery. 
- Be given Radiation treatment in 1-5 treatments
- Be involved for about 2 years
Participating Institutions:
  • Duke University Health System : Radiation Oncology DCI Clinical Research Team
View this trial at ClinicalTrials.gov

Pre-Op IG-IMPT or IMRT with SIB (Retroperitoneal Sarcomas)
Principal Investigator: Blazer, Dan
Protocol Number: PRO00075846

Age Group: Adult
Scope: National

Phase: I/II (Cancer Control)
Disease Site: Soft Tissue

Contact: DCI Clinical Research Team, Radiation Oncology
Email:

What is the Condition Being Studied?
Retroperitoneal Sarcomas
What is the Purpose of this Study?
We are doing this study to look at the use of IG-IMRT as a treatment for retroperitoneal sarcomas. 
Who Can Participate in the Study?
Adults who:
- Are diagnosed with primary soft tissue sarcoma of the retroperitoneum
- Have a life expectancy of greater than 2 years
What is Involved?
If you choose to join this study, you will: 
- Undergo radiation therapy using IG-IMRT before surgery for the removal of your tumor. 
- Receive a standard dose of radiation that will be given to the majority of the tumor and at the same time, a higher dose of radiation will be given to certain areas of the tumor identified as higher risks.
- Schedule your surgery following radiation therapy with your surgeon.
- Be involved in the study for about 6 months.
Participating Institutions:
  • Duke University Health System : Radiation Oncology DCI Clinical Research Team
View this trial at ClinicalTrials.gov

BMX-HN-001 for Locally Advanced Head and Neck Cancer
Principal Investigator: Brizel, David
Protocol Number: PRO00076742

Age Group: Adult
Scope: National

Phase: I (Cancer Control)
Disease Site: Lip, Oral Cavity and Pharynx

Contact: DCI Clinical Research Team, Radiation Oncology
Email:

What is the Condition Being Studied?
Head and Neck Cancer
What is the Purpose of this Study?
We are doing this study to understand how the study drug BMX-001 works to improve the side effects of treatment including sore mouth/throat, skin changes, swallowing difficulties and dry mouth.
Who Can Participate in the Study?
Adults who: 
- Are diagnosed with head and neck cancer for whom cisplatin and radiation would be considered appropriate care
- Have a radiation treatment plan that has a daily radiation treatment
- Have a negative pregnancy test 
What is Involved?
If you choose to join this study, you will: 
- Have screening tests and procedures such as blood tests, physical exam and imaging
- Get the study drug, BMX-001, as a shot under your skin along with radiation therapy and the chemotherapy drug, cisplatin
- Get the first shot of BMX-001 a couple of days before radiation therapy (RT) starts, and BMX-001 is given for eight weeks
- Be involved in this study for about 1 year
Participating Institutions:
  • Duke University Health System : Radiation Oncology DCI Clinical Research Team
View this trial at ClinicalTrials.gov

PROCEED (Esophago-gastric Cancer)
Principal Investigator: Palta, Manisha
Protocol Number: PRO00081010

Age Group: Adult
Scope: Local

Phase: II (Cancer Control)
Disease Site: Esophagus

Contact: DCI Clinical Research Team, Radiation Oncology
Email:

What is the Condition Being Studied?
Esophago-gastric cancer
What is the Purpose of this Study?
We are doing this study to learn whether before surgery chemoradiotherapy with pembrolizumab followed by surgery improves how your cancer responds.
Who Can Participate in the Study?
Adults with invasive esophageal, gastroesophageal or gastric adenocarcinoma that has not spread and who are planning to have chemoradiation before surgery.
What is Involved?
If you join the study, you will have:
- a physical exam and other tests. 
- Imaging scans (Computerized Tomography (CT) or Positron Emission Tomography (PET)), 
- An endoscopic ultrasound   
- 5 Blood samples  
You will also:
- Receive Pembrolizumab combined with carboplatin, paclitaxel and radiation therapy before surgery  
- Receive Pembrolizumab after surgery.
Participating Institutions:
  • Duke University Health System : Radiation Oncology DCI Clinical Research Team
View this trial at ClinicalTrials.gov

Accelerated Adaptive Radiation Therapy for NSCLC (ADAPT) (Lung Cancer)
Principal Investigator: Kelsey, Christopher
Protocol Number: PRO00083154

Age Group: Adult
Scope: Local

Phase: II (Cancer Control)
Disease Site: Lung

Contact: DCI Clinical Research Team, Radiation Oncology
Email:

What is the Condition Being Studied?
Non-small cell lung cancer for which surgery is not an option
What is the Purpose of this Study?
We are doing this study to learn whether giving radiation treatment in combination with chemotherapy in slightly higher daily doses over a shorter period of time could improve how lung cancer responds to treatment and improve overall progression free survival.
Who Can Participate in the Study?
Adults with unresectable stage II, IIIA, & IIIB non-small cell lung cancer who have not yet received chemotherapy or radiation for their disease.
What is Involved?
If you choose to join this study:
You will receive standard of care chemotherapy with radiation therapy for about 5 weeks.  
At the end of week 4 of radiation you will have a PET-CT scan to see if you are responding to treatment.  

If you have a complete response, you will complete radiation therapy at 5 weeks   

If you have residual disease on the PET-CT you may be eligible for an extra week of radiation therapy.  

You may receive consolidation chemotherapy and/or immunotherapy 4-8 weeks after radiation therapy at the discretion of your treating medical oncologist.
Participating Institutions:
  • Duke University Health System : Radiation Oncology DCI Clinical Research Team
View this trial at ClinicalTrials.gov

PROVE-HCC for Liver Cancer
Principal Investigator: Palta, Manisha
Protocol Number: PRO00089525

Age Group: Adult
Scope: National

Phase: II (Cancer Control)
Disease Site: Liver

Contact: DCI Clinical Research Team, Radiation Oncology
Email:

What is the Condition Being Studied?
Liver cancer
What is the Purpose of this Study?
We are doing this study to measure quality of life and compare signs such as tiredness, feeling of unease and discomfort in the stomach and pain in patients who have been treated with either PLA or HIGRT for liver cancer.
Who Can Participate in the Study?
Adults who:
-Are diagnosed with 1-3 liver tumors that are less than or equal to 5cm in size
-Can be treated with either PLA or HIGRT
-Have a negative pregnancy test
What is Involved?
If you choose to join this study, you will:
- Be randomly (like drawing numbers from a hat) assigned to one of the following standard of care treatments:
1.  Percutaneous Local Ablation (PLA)- This treatment involves inserting special needles into the liver cancer and using microwaves or radiowaves to damage cancer cells in a way that may cause cell death.
2.  Hypofractionated Image Guided Radiation Therapy (HIGRT)- In this treatment beams of radiation enter the liver from multiple angles to treat the liver cancer over several treatment sessions (typically 5-10 treatments).
- You will be asked to complete two quality of life surveys before treatment and after treatment at one, three and six months, for a total of four times. 
- Be involved in this study for about 8 months
Participating Institutions:
  • Duke University Health System : Radiation Oncology DCI Clinical Research Team
View this trial at ClinicalTrials.gov

Adaptive PET II for Gynecologic and Gastrointestinal Cancers
Principal Investigator: Chino, Junzo
Protocol Number: PRO00089619

Age Group: Adult
Scope: Local

Phase: N/A
Disease Site: Anus; Cervix; Esophagus

Contact: DCI Clinical Research Team, Radiation Oncology
Email:

What is the Condition Being Studied?
Reproductive and Digestive Cancer
What is the Purpose of this Study?
We are doing this study to understand the benefit of using PET scan in addition to the standard of care CT scan to plan for radiation therapy. 

The PET-CT scan may allow your radiation doctor to fine tune the radiation plan or the delivery of radiation to your cancer.
Who Can Participate in the Study?
Adults who:
-Are diagnosed with cervical or vulvar (female reproductive tract), esophageal or anal canal (digestive tract) cancer
-Have a negative pregnancy test    
What is Involved?
If you choose to join this study, you will:
- have 2  PET scans in addition to computed tomography (CT) scans
- have the first PET-CT scan before the start of radiation therapy 
- have the second PET-CT scan during radiation therapy
- be involved in the study for about 6-8 weeks
Participating Institutions:
  • Duke University Health System : Radiation Oncology DCI Clinical Research Team
View this trial at ClinicalTrials.gov

PaRTNer - Quality of Life in Head and Neck Cancer
Principal Investigator: Mowery, Yvonne
Protocol Number: PRO00092590

Age Group: Adult
Scope: Local

Phase: N/A
Disease Site: Lip, Oral Cavity and Pharynx

Contact: DCI Clinical Research Team, Radiation Oncology
Email:

What is the Condition Being Studied?
Head and Neck cancer
What is the Purpose of this Study?
We are doing this study to understand how out of pocket costs and financial stress may affect symptoms and quality of life in patients treated for head and neck cancer.
Who Can Participate in the Study?
Adults who:
- Are able to read and write in English
- Are diagnosed with head and neck cancer 
- Have a cancer treatment plan that includes radiation therapy or  radiation therapy and chemotherapy
What is Involved?
If you choose to join this study, you will:
- Be asked to complete quality of life questionnaires before the start of your treatment and at 3 months and 6 months after treatment is finished. 
-- The questionnaires will ask you for information such as your family, marital status, work status, educational level, symptoms and quality of life, your financial health and actual costs of cancer care. 
- Be willing to spend about 20 minutes to complete the questionnaires. 
- Be involved in the study for about 8 months.
Participating Institutions:
  • Duke University Health System : Radiation Oncology DCI Clinical Research Team
View this trial at ClinicalTrials.gov

BMX-MBM-001 (Brain Metastases)
Principal Investigator: Kirkpatrick, John
Protocol Number: PRO00100377

Age Group: Adult
Scope:

Phase: I/II
Disease Site: Brain and Nervous System

Contact: DCI Clinical Research Team, Radiation Oncology
Email:

What is the Condition Being Studied?
Brain Cancer
What is the Purpose of this Study?
We are doing this study is to find out what effects (good or bad) the study drug, BMX-001, may have on memory and thinking when given with whole brain radiation therapy for cancer that has spread to the brain. 
Who Can Participate in the Study?
Adults who:
- Have primarily been diagnosed with non-small cell lung cancer, breast cancer, melanoma or renal cancer and the cancer has spread to the brain
- Have greater than 10 brain tumors with radiation treatment plan to include whole brain radiation
- Negative pregnancy test for women who could become pregnant
What is Involved?
If you choose to join this study, you will: 
- Be randomly assigned (like the flip of a coin) to one of two groups:
-- Group 1 will get the study drug, BMX-001 in an shot under the skin and whole brain radiation therapy.  You will get the first shot a couple of days before radiation therapy starts, and twice a week during radiation therapy. The last shot is given about 2 days after radiation therapy is finished.

-- Group 2 will only get whole brain radiation therapy 

-- Provide information on your quality of life, side effects of treatment, survival and neurocognitive effects before and after whole brain radiation therapy is given
Participating Institutions:
  • Duke Center for Living/Sarah Stedman Nutrition : Radiation Oncology DCI Clinical Research Team
  • Duke Primary Care : Radiation Oncology DCI Clinical Research Team
  • Duke Private Diagnostic Clinic (PDC) : Radiation Oncology DCI Clinical Research Team
  • Duke University Health System : Radiation Oncology DCI Clinical Research Team
View this trial at ClinicalTrials.gov

DLBCL - Phase II
Principal Investigator: Kelsey, Christopher
Protocol Number: PRO00100510

Age Group: Adult
Scope:

Phase: II
Disease Site: Non-Hodgkin Lymphoma

Contact: DCI Clinical Research Team, Radiation Oncology
Email:

What is the Condition Being Studied?
Diffuse Large B-cell Lymphoma (DLBCL)
What is the Purpose of this Study?
We are doing this study to understand if lowering the radiation dose will work in maintaining high rates of disease control and lessen the short term and long term treatment side effects.
Who Can Participate in the Study?
Adults who:
- Have a diagnosis of stage I-IV DLBCL
- Have completed at least 3 treatments with chemo-immunotherapy
- Have no evidence of cancer in a PET-CT scan done after completion of chemotherapy 
- Have a negative pregnancy test for women who can get pregnant
What is Involved?
If you choose to join this study, you will:
- Be given a lower dose of radiation over 10-13 radiation treatments 
- Have information from tests, exams and procedures that are part of your medical care used for study purposes
-Be involved in the study for about 4-6 weeks 
- Have your progress followed through your electronic medical records for up to 10 years after completion of study treatment.
Participating Institutions:
  • Duke Center for Living/Sarah Stedman Nutrition : Radiation Oncology DCI Clinical Research Team
  • Duke Primary Care : Radiation Oncology DCI Clinical Research Team
  • Duke Private Diagnostic Clinic (PDC) : Radiation Oncology DCI Clinical Research Team
  • Duke University Health System : Radiation Oncology DCI Clinical Research Team
View this trial at ClinicalTrials.gov